SLC5A2 and hydrops fetalis: Moreover, treatment with the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin has now demonstrated to improve outcomes in HFpEF patients, primarily through a reduction in HF hospitalizations comparable to that previously reported in patients with HF and reduced ejection fraction (10).